Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > On GLP-1 agonists US Senate passes anti-patent thicket bill

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 12, 2024 11:34am

124 Views

Post# 36130220

RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket bill

In advance of the US Senate's action against patent thickets, Big Pharma such as Sanofi had 'front-run' this devvelopment by announcing the off-loading of their consumer healthcare divisions, which are heavily protected by patent thickets, in favor of increasingly pronounced investments in biologic therapeutics that target unmet needs and rare diseases in the immunology and oncology spaces.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant